Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

Insights Into The Pathogenesis Of Atp1a1-Related Cmt Disease Using Patient-Specific Ipscs.

Manganelli F, Parisi S, Nolano M, Miceli F, Tozza S, Pisciotta C, Iodice R, Provitera V, Cicatiello R, Zuchner S, Taglialatela M, Russo T, Santoro L.

J Peripher Nerv Syst. 2019 Nov 9. doi: 10.1111/jns.12357. [Epub ahead of print]

PMID:
31707753
2.

Cardiac safety of second-generation H1 -antihistamines when updosed in chronic spontaneous urticaria.

Cataldi M, Maurer M, Taglialatela M, Church MK.

Clin Exp Allergy. 2019 Sep 13. doi: 10.1111/cea.13500. [Epub ahead of print]

PMID:
31519068
3.

Activation of Kv7 Potassium Channels Inhibits Intracellular Ca2+ Increases Triggered By TRPV1-Mediated Pain-Inducing Stimuli in F11 Immortalized Sensory Neurons.

Ambrosino P, Soldovieri MV, Di Zazzo E, Paventi G, Iannotti FA, Mosca I, Miceli F, Franco C, Canzoniero LMT, Taglialatela M.

Int J Mol Sci. 2019 Sep 4;20(18). pii: E4322. doi: 10.3390/ijms20184322.

4.

A novel homozygous KCNQ3 loss-of-function variant causes non-syndromic intellectual disability and neonatal-onset pharmacodependent epilepsy.

Lauritano A, Moutton S, Longobardi E, Tran Mau-Them F, Laudati G, Nappi P, Soldovieri MV, Ambrosino P, Cataldi M, Jouan T, Lehalle D, Maurey H, Philippe C, Miceli F, Vitobello A, Taglialatela M.

Epilepsia Open. 2019 Aug 11;4(3):464-475. doi: 10.1002/epi4.12353. eCollection 2019 Sep.

5.

Epileptic Encephalopathy In A Patient With A Novel Variant In The Kv7.2 S2 Transmembrane Segment: Clinical, Genetic, and Functional Features.

Soldovieri MV, Ambrosino P, Mosca I, Miceli F, Franco C, Canzoniero LMT, Kline-Fath B, Cooper EC, Venkatesan C, Taglialatela M.

Int J Mol Sci. 2019 Jul 10;20(14). pii: E3382. doi: 10.3390/ijms20143382.

6.

Autism and developmental disability caused by KCNQ3 gain-of-function variants.

Sands TT, Miceli F, Lesca G, Beck AE, Sadleir LG, Arrington DK, Schönewolf-Greulich B, Moutton S, Lauritano A, Nappi P, Soldovieri MV, Scheffer IE, Mefford HC, Stong N, Heinzen EL, Goldstein DB, Perez AG, Kossoff EH, Stocco A, Sullivan JA, Shashi V, Gerard B, Francannet C, Bisgaard AM, Tümer Z, Willems M, Rivier F, Vitobello A, Thakkar K, Rajan DS, Barkovich AJ, Weckhuysen S, Cooper EC, Taglialatela M, Cilio MR.

Ann Neurol. 2019 Aug;86(2):181-192. doi: 10.1002/ana.25522. Epub 2019 Jun 26.

PMID:
31177578
7.

A novel mutation in KCNQ3-related benign familial neonatal epilepsy: electroclinical features and neurodevelopmental outcome.

Piro E, Nardello R, Gennaro E, Fontana A, Taglialatela M, Donato Mangano G, Corsello G, Mangano S.

Epileptic Disord. 2019 Feb 1;21(1):87-91. doi: 10.1684/epd.2019.1030.

PMID:
30782577
8.

Gender-related issues in the pharmacology of new anti-obesity drugs.

Cataldi M, Muscogiuri G, Savastano S, Barrea L, Guida B, Taglialatela M, Colao A.

Obes Rev. 2019 Mar;20(3):375-384. doi: 10.1111/obr.12805. Epub 2018 Dec 27. Review.

PMID:
30589980
9.

KCNQ2-Related Disorders.

Miceli F, Soldovieri MV, Joshi N, Weckhuysen S, Cooper E, Taglialatela M.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2010 Apr 27 [updated 2018 Sep 27].

10.

Early Treatment with Quinidine in 2 Patients with Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) Due to Gain-of-Function KCNT1 Mutations: Functional Studies, Clinical Responses, and Critical Issues for Personalized Therapy.

Dilena R, DiFrancesco JC, Soldovieri MV, Giacobbe A, Ambrosino P, Mosca I, Galli MA, Guez S, Fumagalli M, Miceli F, Cattaneo D, Darra F, Gennaro E, Zara F, Striano P, Castellotti B, Gellera C, Varesio C, Veggiotti P, Taglialatela M.

Neurotherapeutics. 2018 Oct;15(4):1112-1126. doi: 10.1007/s13311-018-0657-9.

11.

Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study.

Stoppa G, D'Amore C, Conforti A, Traversa G, Venegoni M, Taglialatela M, Leone R; ESAVIEW Study Group.

BioDrugs. 2018 Aug;32(4):367-375. doi: 10.1007/s40259-018-0293-2.

12.

Identification of a Potent Tryptophan-Based TRPM8 Antagonist With in Vivo Analgesic Activity.

Bertamino A, Iraci N, Ostacolo C, Ambrosino P, Musella S, Di Sarno V, Ciaglia T, Pepe G, Sala M, Soldovieri MV, Mosca I, Gonzalez-Rodriguez S, Fernandez-Carvajal A, Ferrer-Montiel A, Novellino E, Taglialatela M, Campiglia P, Gomez-Monterrey I.

J Med Chem. 2018 Jul 26;61(14):6140-6152. doi: 10.1021/acs.jmedchem.8b00545. Epub 2018 Jul 10.

PMID:
29939028
13.

De novo gain-of-function variants in KCNT2 as a novel cause of developmental and epileptic encephalopathy.

Ambrosino P, Soldovieri MV, Bast T, Turnpenny PD, Uhrig S, Biskup S, Döcker M, Fleck T, Mosca I, Manocchio L, Iraci N, Taglialatela M, Lemke JR.

Ann Neurol. 2018 Jun;83(6):1198-1204. doi: 10.1002/ana.25248.

PMID:
29740868
14.

Kv7.3 Compound Heterozygous Variants in Early Onset Encephalopathy Reveal Additive Contribution of C-Terminal Residues to PIP2-Dependent K+ Channel Gating.

Ambrosino P, Freri E, Castellotti B, Soldovieri MV, Mosca I, Manocchio L, Gellera C, Canafoglia L, Franceschetti S, Salis B, Iraci N, Miceli F, Ragona F, Granata T, DiFrancesco JC, Taglialatela M.

Mol Neurobiol. 2018 Aug;55(8):7009-7024. doi: 10.1007/s12035-018-0883-5. Epub 2018 Jan 30.

PMID:
29383681
15.

Pharmacological Targeting of Neuronal Kv7.2/3 Channels: A Focus on Chemotypes and Receptor Sites.

Miceli F, Soldovieri MV, Ambrosino P, Manocchio L, Mosca I, Taglialatela M.

Curr Med Chem. 2018;25(23):2637-2660. doi: 10.2174/0929867324666171012122852. Review.

PMID:
29022505
16.

KCNQ3-Related Disorders.

Miceli F, Soldovieri MV, Joshi N, Weckhuysen S, Cooper EC, Taglialatela M.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2014 May 22 [updated 2017 Sep 7].

17.

Differential Regulation of PI(4,5)P2 Sensitivity of Kv7.2 and Kv7.3 Channels by Calmodulin.

Gomis-Perez C, Soldovieri MV, Malo C, Ambrosino P, Taglialatela M, Areso P, Villarroel A.

Front Mol Neurosci. 2017 May 1;10:117. doi: 10.3389/fnmol.2017.00117. eCollection 2017.

18.

Effects of natural and synthetic isothiocyanate-based H2S-releasers against chemotherapy-induced neuropathic pain: Role of Kv7 potassium channels.

Di Cesare Mannelli L, Lucarini E, Micheli L, Mosca I, Ambrosino P, Soldovieri MV, Martelli A, Testai L, Taglialatela M, Calderone V, Ghelardini C.

Neuropharmacology. 2017 Jul 15;121:49-59. doi: 10.1016/j.neuropharm.2017.04.029. Epub 2017 Apr 19.

PMID:
28431970
19.

Neonatal nonepileptic myoclonus is a prominent clinical feature of KCNQ2 gain-of-function variants R201C and R201H.

Mulkey SB, Ben-Zeev B, Nicolai J, Carroll JL, Grønborg S, Jiang YH, Joshi N, Kelly M, Koolen DA, Mikati MA, Park K, Pearl PL, Scheffer IE, Spillmann RC, Taglialatela M, Vieker S, Weckhuysen S, Cooper EC, Cilio MR.

Epilepsia. 2017 Mar;58(3):436-445. doi: 10.1111/epi.13676. Epub 2017 Jan 31.

20.

Early-onset epileptic encephalopathy caused by a reduced sensitivity of Kv7.2 potassium channels to phosphatidylinositol 4,5-bisphosphate.

Soldovieri MV, Ambrosino P, Mosca I, De Maria M, Moretto E, Miceli F, Alaimo A, Iraci N, Manocchio L, Medoro A, Passafaro M, Taglialatela M.

Sci Rep. 2016 Dec 1;6:38167. doi: 10.1038/srep38167.

21.

Rapid and safe response to low-dose carbamazepine in neonatal epilepsy.

Sands TT, Balestri M, Bellini G, Mulkey SB, Danhaive O, Bakken EH, Taglialatela M, Oldham MS, Vigevano F, Holmes GL, Cilio MR.

Epilepsia. 2016 Dec;57(12):2019-2030. doi: 10.1111/epi.13596. Epub 2016 Nov 26.

22.

Infantile spasms and encephalopathy without preceding neonatal seizures caused by KCNQ2 R198Q, a gain-of-function variant.

Millichap JJ, Miceli F, De Maria M, Keator C, Joshi N, Tran B, Soldovieri MV, Ambrosino P, Shashi V, Mikati MA, Cooper EC, Taglialatela M.

Epilepsia. 2017 Jan;58(1):e10-e15. doi: 10.1111/epi.13601. Epub 2016 Nov 9.

23.

KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients.

Millichap JJ, Park KL, Tsuchida T, Ben-Zeev B, Carmant L, Flamini R, Joshi N, Levisohn PM, Marsh E, Nangia S, Narayanan V, Ortiz-Gonzalez XR, Patterson MC, Pearl PL, Porter B, Ramsey K, McGinnis EL, Taglialatela M, Tracy M, Tran B, Venkatesan C, Weckhuysen S, Cooper EC.

Neurol Genet. 2016 Aug 22;2(5):e96. doi: 10.1212/NXG.0000000000000096. eCollection 2016 Oct.

24.

β-Adrenergic response is counteracted by extremely-low-frequency pulsed electromagnetic fields in beating cardiomyocytes.

Cornacchione M, Pellegrini M, Fassina L, Mognaschi ME, Di Siena S, Gimmelli R, Ambrosino P, Soldovieri MV, Taglialatela M, Gianfrilli D, Isidori AM, Lenzi A, Naro F.

J Mol Cell Cardiol. 2016 Sep;98:146-58. doi: 10.1016/j.yjmcc.2016.07.004. Epub 2016 Jul 11.

PMID:
27418252
25.

Tryptamine-Based Derivatives as Transient Receptor Potential Melastatin Type 8 (TRPM8) Channel Modulators.

Bertamino A, Ostacolo C, Ambrosino P, Musella S, Di Sarno V, Ciaglia T, Soldovieri MV, Iraci N, Fernandez Carvajal A, de la Torre-Martinez R, Ferrer-Montiel A, Gonzalez Muniz R, Novellino E, Taglialatela M, Campiglia P, Gomez-Monterrey I.

J Med Chem. 2016 Mar 10;59(5):2179-91. doi: 10.1021/acs.jmedchem.5b01914. Epub 2016 Feb 17.

PMID:
26847872
26.

Characterization of two de novoKCNT1 mutations in children with malignant migrating partial seizures in infancy.

Rizzo F, Ambrosino P, Guacci A, Chetta M, Marchese G, Rocco T, Soldovieri MV, Manocchio L, Mosca I, Casara G, Vecchi M, Taglialatela M, Coppola G, Weisz A.

Mol Cell Neurosci. 2016 Apr;72:54-63. doi: 10.1016/j.mcn.2016.01.004. Epub 2016 Jan 16.

PMID:
26784557
27.

Expression and function of Kv7.4 channels in rat cardiac mitochondria: possible targets for cardioprotection.

Testai L, Barrese V, Soldovieri MV, Ambrosino P, Martelli A, Vinciguerra I, Miceli F, Greenwood IA, Curtis MJ, Breschi MC, Sisalli MJ, Scorziello A, Canduela MJ, Grandes P, Calderone V, Taglialatela M.

Cardiovasc Res. 2016 May 1;110(1):40-50. doi: 10.1093/cvr/cvv281. Epub 2015 Dec 29.

PMID:
26718475
28.

Molecular pathophysiology and pharmacology of the voltage-sensing module of neuronal ion channels.

Miceli F, Soldovieri MV, Ambrosino P, De Maria M, Manocchio L, Medoro A, Taglialatela M.

Front Cell Neurosci. 2015 Jul 15;9:259. doi: 10.3389/fncel.2015.00259. eCollection 2015. Review.

29.

Epilepsy-causing mutations in Kv7.2 C-terminus affect binding and functional modulation by calmodulin.

Ambrosino P, Alaimo A, Bartollino S, Manocchio L, De Maria M, Mosca I, Gomis-Perez C, Alberdi A, Scambia G, Lesca G, Villarroel A, Taglialatela M, Soldovieri MV.

Biochim Biophys Acta. 2015 Sep;1852(9):1856-66. doi: 10.1016/j.bbadis.2015.06.012. Epub 2015 Jun 12.

30.

Protective role of Kv7 channels in oxygen and glucose deprivation-induced damage in rat caudate brain slices.

Barrese V, Taglialatela M, Greenwood IA, Davidson C.

J Cereb Blood Flow Metab. 2015 Oct;35(10):1593-600. doi: 10.1038/jcbfm.2015.83. Epub 2015 May 13.

31.

Early-onset epileptic encephalopathy caused by gain-of-function mutations in the voltage sensor of Kv7.2 and Kv7.3 potassium channel subunits.

Miceli F, Soldovieri MV, Ambrosino P, De Maria M, Migliore M, Migliore R, Taglialatela M.

J Neurosci. 2015 Mar 4;35(9):3782-93. doi: 10.1523/JNEUROSCI.4423-14.2015.

32.

A novel KCNQ3 mutation in familial epilepsy with focal seizures and intellectual disability.

Miceli F, Striano P, Soldovieri MV, Fontana A, Nardello R, Robbiano A, Bellini G, Elia M, Zara F, Taglialatela M, Mangano S.

Epilepsia. 2015 Feb;56(2):e15-20. doi: 10.1111/epi.12887. Epub 2014 Dec 19.

33.

Functional and biochemical interaction between PPARα receptors and TRPV1 channels: Potential role in PPARα agonists-mediated analgesia.

Ambrosino P, Soldovieri MV, De Maria M, Russo C, Taglialatela M.

Pharmacol Res. 2014 Sep;87:113-22. doi: 10.1016/j.phrs.2014.06.015. Epub 2014 Jul 8.

PMID:
25014183
34.

Critical role of large-conductance calcium- and voltage-activated potassium channels in leptin-induced neuroprotection of N-methyl-d-aspartate-exposed cortical neurons.

Mancini M, Soldovieri MV, Gessner G, Wissuwa B, Barrese V, Boscia F, Secondo A, Miceli F, Franco C, Ambrosino P, Canzoniero LM, Bauer M, Hoshi T, Heinemann SH, Taglialatela M.

Pharmacol Res. 2014 Sep;87:80-6. doi: 10.1016/j.phrs.2014.06.010. Epub 2014 Jun 26.

35.

The endocannabinoid 2-AG controls skeletal muscle cell differentiation via CB1 receptor-dependent inhibition of Kv7 channels.

Iannotti FA, Silvestri C, Mazzarella E, Martella A, Calvigioni D, Piscitelli F, Ambrosino P, Petrosino S, Czifra G, Bíró T, Harkany T, Taglialatela M, Di Marzo V.

Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):E2472-81. doi: 10.1073/pnas.1406728111. Epub 2014 Jun 3.

36.

The ever changing moods of calmodulin: how structural plasticity entails transductional adaptability.

Villarroel A, Taglialatela M, Bernardo-Seisdedos G, Alaimo A, Agirre J, Alberdi A, Gomis-Perez C, Soldovieri MV, Ambrosino P, Malo C, Areso P.

J Mol Biol. 2014 Jul 29;426(15):2717-35. doi: 10.1016/j.jmb.2014.05.016. Epub 2014 May 22. Review.

PMID:
24857860
37.

Large conductance calcium-activated potassium channels: their expression and modulation of glutamate release from nerve terminals isolated from rat trigeminal caudal nucleus and cerebral cortex.

Samengo I, Currò D, Barrese V, Taglialatela M, Martire M.

Neurochem Res. 2014 May;39(5):901-10. doi: 10.1007/s11064-014-1287-1. Epub 2014 Mar 26.

PMID:
24667981
38.

Novel KCNQ2 and KCNQ3 mutations in a large cohort of families with benign neonatal epilepsy: first evidence for an altered channel regulation by syntaxin-1A.

Soldovieri MV, Boutry-Kryza N, Milh M, Doummar D, Heron B, Bourel E, Ambrosino P, Miceli F, De Maria M, Dorison N, Auvin S, Echenne B, Oertel J, Riquet A, Lambert L, Gerard M, Roubergue A, Calender A, Mignot C, Taglialatela M, Lesca G.

Hum Mutat. 2014 Mar;35(3):356-67. doi: 10.1002/humu.22500. Epub 2014 Jan 13.

PMID:
24375629
39.

New advances in beta-blocker therapy in heart failure.

Barrese V, Taglialatela M.

Front Physiol. 2013 Nov 14;4:323. doi: 10.3389/fphys.2013.00323. eCollection 2013. Review.

40.

Expression and motor functional roles of voltage-dependent type 7 K(+) channels in the human taenia coli.

Adduci A, Martire M, Taglialatela M, Arena V, Rizzo G, Coco C, Currò D.

Eur J Pharmacol. 2013 Dec 5;721(1-3):12-20. doi: 10.1016/j.ejphar.2013.09.061. Epub 2013 Oct 10.

PMID:
24120659
41.

Isoxazole derivatives as potent transient receptor potential melastatin type 8 (TRPM8) agonists.

Ostacolo C, Ambrosino P, Russo R, Lo Monte M, Soldovieri MV, Laneri S, Sacchi A, Vistoli G, Taglialatela M, Calignano A.

Eur J Med Chem. 2013 Nov;69:659-69. doi: 10.1016/j.ejmech.2013.08.056. Epub 2013 Sep 20.

PMID:
24095758
42.

Subtype-selective activation of K(v)7 channels by AaTXKβ₂₋₆₄, a novel toxin variant from the Androctonus australis scorpion venom.

Landoulsi Z, Miceli F, Palmese A, Amoresano A, Marino G, El Ayeb M, Taglialatela M, Benkhalifa R.

Mol Pharmacol. 2013 Nov;84(5):763-73. doi: 10.1124/mol.113.088971. Epub 2013 Sep 9.

PMID:
24019223
43.

Genotype-phenotype correlations in neonatal epilepsies caused by mutations in the voltage sensor of K(v)7.2 potassium channel subunits.

Miceli F, Soldovieri MV, Ambrosino P, Barrese V, Migliore M, Cilio MR, Taglialatela M.

Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4386-91. doi: 10.1073/pnas.1216867110. Epub 2013 Feb 25.

44.

Genetic testing in benign familial epilepsies of the first year of life: clinical and diagnostic significance.

Zara F, Specchio N, Striano P, Robbiano A, Gennaro E, Paravidino R, Vanni N, Beccaria F, Capovilla G, Bianchi A, Caffi L, Cardilli V, Darra F, Bernardina BD, Fusco L, Gaggero R, Giordano L, Guerrini R, Incorpora G, Mastrangelo M, Spaccini L, Laverda AM, Vecchi M, Vanadia F, Veggiotti P, Viri M, Occhi G, Budetta M, Taglialatela M, Coviello DA, Vigevano F, Minetti C.

Epilepsia. 2013 Mar;54(3):425-36. doi: 10.1111/epi.12089. Epub 2013 Jan 29.

45.

Vasorelaxation by hydrogen sulphide involves activation of Kv7 potassium channels.

Martelli A, Testai L, Breschi MC, Lawson K, McKay NG, Miceli F, Taglialatela M, Calderone V.

Pharmacol Res. 2013 Apr;70(1):27-34. doi: 10.1016/j.phrs.2012.12.005. Epub 2013 Jan 1.

PMID:
23287425
46.

Specification of skeletal muscle differentiation by repressor element-1 silencing transcription factor (REST)-regulated Kv7.4 potassium channels.

Iannotti FA, Barrese V, Formisano L, Miceli F, Taglialatela M.

Mol Biol Cell. 2013 Feb;24(3):274-84. doi: 10.1091/mbc.E11-12-1044. Epub 2012 Dec 14.

47.

Addressing the use of PDIF-CN2 molecules in the development of n-type organic field-effect transistors for biosensing applications.

Barra M, Viggiano D, Ambrosino P, Bloisi F, Di Girolamo FV, Soldovieri MV, Taglialatela M, Cassinese A.

Biochim Biophys Acta. 2013 Sep;1830(9):4365-73. doi: 10.1016/j.bbagen.2012.11.025. Epub 2012 Dec 6.

PMID:
23220699
48.

Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide.

Ambrosino P, Soldovieri MV, Russo C, Taglialatela M.

Br J Pharmacol. 2013 Mar;168(6):1430-44. doi: 10.1111/bph.12029.

49.

Gating currents from Kv7 channels carrying neuronal hyperexcitability mutations in the voltage-sensing domain.

Miceli F, Vargas E, Bezanilla F, Taglialatela M.

Biophys J. 2012 Mar 21;102(6):1372-82. doi: 10.1016/j.bpj.2012.02.004. Epub 2012 Mar 20.

50.

Molecular and pharmacological evidence for a facilitatory functional role of pre-synaptic GLUK2/3 kainate receptors on GABA release in rat trigeminal caudal nucleus.

Samengo I, Currò D, Navarra P, Barrese V, Taglialatela M, Martire M.

Eur J Pain. 2012 Sep;16(8):1148-57. doi: 10.1002/j.1532-2149.2012.00122.x. Epub 2012 Mar 6.

Supplemental Content

Loading ...
Support Center